Rieken, Stefan

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Chung, Inn"],["dc.contributor.author","Christopoulos, Petros"],["dc.contributor.author","Krisam, Johannes"],["dc.contributor.author","Schneider, Marc A."],["dc.contributor.author","Brückner, Lena"],["dc.contributor.author","Mueller, Daniel Wilhelm"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2021-04-14T08:23:57Z"],["dc.date.available","2021-04-14T08:23:57Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1186/s12885-020-07264-8"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17530"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81111"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1471-2407"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","6563"],["dc.bibliographiccitation.journal","Cancer Management and Research"],["dc.bibliographiccitation.lastpage","6569"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Aufderstrasse, Sophie"],["dc.contributor.author","König, Laila"],["dc.contributor.author","Adeberg, Sebastian"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Christopoulos, Petros"],["dc.contributor.author","Shafie, Rami A El"],["dc.contributor.author","Hörner-Rieber, Juliane"],["dc.contributor.author","Kappes, Jutta"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Herth, Felix"],["dc.contributor.author","Steins, Martin"],["dc.contributor.author","Debus, Jürgen"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2020-07-16T10:32:15Z"],["dc.date.available","2020-07-16T10:32:15Z"],["dc.date.issued","2018"],["dc.description.abstract","Systemic inflammation appears to play a role in the progression of numerous solid tumors by promoting tumor proliferation. Our current study aimed to evaluate the role of inflammatory markers in limited disease (LD) small-cell lung cancer (SCLC) patients undergoing thoracic chemoradiotherapy (TCR)."],["dc.identifier.doi","10.2147/CMAR.S180990"],["dc.identifier.pmid","30555261"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67162"],["dc.language.iso","en"],["dc.relation.issn","1179-1322"],["dc.title","Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","1011"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Christopoulos, Petros"],["dc.contributor.author","Chung, Inn"],["dc.contributor.author","Cvetkovic, Jelena"],["dc.contributor.author","Feißt, Manuel"],["dc.contributor.author","Krisam, Johannes"],["dc.contributor.author","Schneider, Marc A."],["dc.contributor.author","Heußel, Claus P."],["dc.contributor.author","Kreuter, Michael"],["dc.contributor.author","Müller, Daniel W."],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Rieken, Stefan"],["dc.date.accessioned","2022-09-26T07:37:55Z"],["dc.date.available","2022-09-26T07:37:55Z"],["dc.date.issued","2022-09-24"],["dc.date.updated","2022-09-25T03:19:30Z"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approval of this regimen. At the same time, accumulating (pre-)clinical data suggest synergisms of radiotherapy and immunotherapy via the radiation-mediated induction of anti-tumor immunogenicity. Combining the recent findings, the TREASURE trial aims at further enhancing response to upfront chemo-immunotherapy by the addition of thoracic radiotherapy (TRT).\r\n \r\n \r\n Methods/design\r\n The TREASURE trial is a randomized, multicenter, phase II clinical trial (\r\n ClinicalTrials.gov\r\n \r\n identifier, NCT04462276). One hundred four patients suffering from extensive disease (ED) SCLC, with any response to the standard of care induction chemo-immunotherapy will be randomized to receive atezolizumab maintenance therapy with or without TRT. The primary endpoint of this study is overall survival (OS). Secondary endpoints include further measures of efficacy, safety, and the collection of biomarker samples. A safety interim analysis will take place after n = 23 patients receiving TRT have been observed for three months after the end of TRT.\r\n \r\n \r\n Discussion\r\n This trial will investigate whether treatment efficacy can be improved by adding TRT to atezolizumab maintenance therapy in ED SCLC patients with any response after chemo-immunotherapy. Safety and feasibility of such a regimen will be evaluated, and biomaterials for a translational research project will be collected. Together, the results of this trial will deepen our comprehension of how checkpoint inhibition and radiotherapy interact and contribute to the evolving landscape of SCLC therapy.\r\n \r\n \r\n Trial registration\r\n \r\n\r\n Clinicaltrials.gov\r\n \r\n identifier: \r\n NCT04462276\r\n \r\n (Date of initial registration: 8th July 2020), \r\n https://clinicaltrials.gov/ct2/show/NCT04462276\r\n \r\n \r\n Eudra-CT Number: 2019-003916-29 (Date of initial registration: 30th March 2020), \r\n https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003916-29/DE"],["dc.identifier.citation","BMC Cancer. 2022 Sep 24;22(1):1011"],["dc.identifier.doi","10.1186/s12885-022-10074-9"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114285"],["dc.language.iso","en"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","Extensive disease small cell lung cancer"],["dc.subject","SCLC"],["dc.subject","Radioimmuntherapy"],["dc.subject","Thoracic radiotherapy"],["dc.subject","Atezolizumab"],["dc.subject","Anti-PD-L1 monoclonal antibody"],["dc.subject","First-line therapy"],["dc.title","Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","782"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Thoracic Disease"],["dc.bibliographiccitation.lastpage","793"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","von Eiff, Damian"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Chung, Inn"],["dc.contributor.author","Bernhardt, Denise"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Liersch, Stephan"],["dc.contributor.author","Muley, Thomas"],["dc.contributor.author","Kobinger, Sonja"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Christopoulos, Petros"],["dc.contributor.author","Steins, Martin"],["dc.date.accessioned","2020-07-16T10:32:04Z"],["dc.date.available","2020-07-16T10:32:04Z"],["dc.date.issued","2020-03"],["dc.description.abstract","Etoposide-/platinum-based chemotherapy is the standard first-line treatment for extensive-disease small cell lung cancer (SCLC), but responses are short-lived and subsequent options limited. Here, we present our experience with paclitaxel in advanced treatment lines."],["dc.identifier.doi","10.21037/jtd.2019.12.74"],["dc.identifier.pmid","32274145"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/67159"],["dc.language.iso","en"],["dc.relation.issn","2072-1439"],["dc.title","Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2589"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","International Journal of Cancer"],["dc.bibliographiccitation.lastpage","2598"],["dc.bibliographiccitation.volume","142"],["dc.contributor.author","Christopoulos, Petros"],["dc.contributor.author","Endris, Volker"],["dc.contributor.author","Bozorgmehr, Farastuk"],["dc.contributor.author","Elsayed, Mei"],["dc.contributor.author","Kirchner, Martina"],["dc.contributor.author","Ristau, Jonas"],["dc.contributor.author","Buchhalter, Ivo"],["dc.contributor.author","Penzel, Roland"],["dc.contributor.author","Herth, Felix J"],["dc.contributor.author","Heussel, Claus P"],["dc.contributor.author","Eichhorn, Martin"],["dc.contributor.author","Muley, Thomas"],["dc.contributor.author","Meister, Michael"],["dc.contributor.author","Fischer, Jürgen R"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Warth, Arne"],["dc.contributor.author","Bischoff, Helge"],["dc.contributor.author","Schirmacher, Peter"],["dc.contributor.author","Stenzinger, Albrecht"],["dc.contributor.author","Thomas, Michael"],["dc.date.accessioned","2020-07-10T08:19:50Z"],["dc.date.available","2020-07-10T08:19:50Z"],["dc.date.issued","2018"],["dc.description.abstract","In order to identify anaplastic lymphoma kinase-driven non-small cell lung cancer (ALK+ NSCLC) patients with a worse outcome, who might require alternative therapeutic approaches, we retrospectively analyzed all stage IV cases treated at our institutions with one of the main echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion variants V1, V2 and V3 as detected by next-generation sequencing or reverse transcription-polymerase chain reaction (n = 67). Progression under tyrosine kinase inhibitor (TKI) treatment was evaluated both according to Response Evaluation Criteria in Solid Tumors (RECIST) and by the need to change systemic therapy. EML4-ALK fusion variants V1, V2 and V3 were found in 39%, 10% and 51% of cases, respectively. Patients with V3-driven tumors had more metastatic sites at diagnosis than cases with the V1 and V2 variants (mean 3.3 vs. 1.9 and 1.6, p = 0.005), which suggests increased disease aggressiveness. Furthermore, V3-positive status was associated with earlier failure after treatment with first and second-generation ALK TKI (median progression-free survival [PFS] by RECIST in the first line 7.3 vs. 39.3 months, p = 0.01), platinum-based combination chemotherapy (median PFS 5.4 vs. 15.2 months for the first line, p = 0.008) and cerebral radiotherapy (median brain PFS 6.1 months vs. not reached for cerebral radiotherapy during first-line treatment, p = 0.028), and with inferior overall survival (39.8 vs. 59.6 months in median, p = 0.017). Thus, EML4-ALK fusion variant V3 is a high-risk feature for ALK+ NSCLC. Determination of V3 status should be considered as part of the initial workup for this entity in order to select patients for more aggressive surveillance and treatment strategies."],["dc.identifier.doi","10.1002/ijc.31275"],["dc.identifier.pmid","29363116"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66979"],["dc.language.iso","en"],["dc.relation.eissn","1097-0215"],["dc.relation.issn","0020-7136"],["dc.title","EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]